Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 108

• Price / Volume Information    Yesterday's Closing Price: $31.51 Daily Weekly Monthly 20 Day Moving Average: 1,182,521 shares Shares Outstanding: 38.91 (millions) Market Capitalization: $1,226.17 (millions) Beta: 2.47 52 Week High: $74.10 52 Week Low: $19.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.43% -10.38% 12 Week 12.06% 23.20% Year To Date -16.60% 1.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 CORTLANDT STREET 16TH FLOOR - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 38.91 Most Recent Split Date: (:1) Beta: 2.47 Market Capitalization: $1,226.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 83.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.05% vs. Previous Quarter: -14.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -389.71 12/31/21 - -230.72 09/30/21 - -154.94 ROA 03/31/22 - -129.08 12/31/21 - -101.37 09/30/21 - -81.96 Current Ratio 03/31/22 - 3.54 12/31/21 - 3.75 09/30/21 - 4.66 Quick Ratio 03/31/22 - 3.54 12/31/21 - 3.75 09/30/21 - 4.66 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.38 12/31/21 - 0.41 09/30/21 - 1.13 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 3.36 12/31/21 - 3.14 09/30/21 - 1.15 Debt-to-Capital 03/31/22 - 77.04 12/31/21 - 75.85 09/30/21 - 53.51

Powered by Zacks Investment Research ©